Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
40 hedge funds and large institutions have $20.5M invested in Kezar Life Sciences in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 4 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
2.01% more ownership
Funds ownership: 59.21% → 61.22% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $21.1M → $20.5M (-$627K)
2% less funds holding
Funds holding: 41 → 40 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$973K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$299K |
| 3 |
BlackRock
New York
|
+$64.5K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.8K |
| 5 |
Renaissance Technologies
New York
|
+$7.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$214K |
| 2 |
Goldman Sachs
New York
|
-$138K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$125K |
| 4 |
Squarepoint
New York
|
-$99.1K |
| 5 |
CHAM
Clear Harbor Asset Management
Stamford,
Connecticut
|
-$77.1K |
KZR Hedge Fund Activity: Q2 2025 in Review
40 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2025, worth a combined $20.5M — down 3% from $21.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of KZR and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 11 added.
The largest buyer was BML Capital Management, adding an estimated $973K. The largest seller was Sphera Funds Management, cutting an estimated $214K.
- 40 institutional investors held Kezar Life Sciences (KZR) as of Q2 2025, down from 41 in Q1 2025.
- Funds reported $20.5M of Kezar Life Sciences stock for Q2 2025, down 3% quarter-over-quarter.
- 3 funds opened new Kezar Life Sciences positions in Q2 2025 and 4 closed out, a net change of -1 holder.
- The largest Kezar Life Sciences buyer in Q2 2025 was BML Capital Management, an estimated $973K added.
- The largest Kezar Life Sciences seller in Q2 2025 was Sphera Funds Management, an estimated $214K sold.
Based on aggregated 13F filings for Q2 2025.